QUASAR Study Shows Oncotype DX Gauges Colon Cancer Recurrence Risk, Doesn't Predict Treatment Benefit | GenomeWeb

By Turna Ray

With the publication this week of a validation study for its Oncotype DX colon cancer test, Genomic Health is hoping that more insurers will now be willing to pay for the diagnostic.

However, the same study was unable to confirm that the test can predict which patients will benefit from treatment with chemotherapy — a finding that may negatively impact the test's adoption, according to some industry observers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.